Diverse Signaling Pathways and Current Status of Molecular Targeted Treatments for Hepatocellular Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality.
• HCC development involves complex molecular alterations like chromosomal instability and gene mutations.
• Dysregulated cell signaling pathways in apoptosis, proliferation, and angiogenesis are implicated in HCC.

Purpose of the Study:

• To explore novel therapeutic strategies for Hepatocellular carcinoma (HCC).
• To evaluate the potential of targeted therapies and combination regimens in HCC treatment.
• To understand how new treatments impact the management of HCC.

Main Methods:

• Review of existing literature on HCC molecular mechanisms and therapeutic targets.
• Analysis of clinical trial data for targeted agents and combination therapies.
• Examination of FDA-approved treatments and investigational drugs for HCC.

Main Results:

• Sorafenib is the sole FDA-approved drug for HCC, but combination therapies show promise.
• Combinations of sorafenib with chemotherapy (doxorubicin, oxaliplatin, cisplatin) and monoclonal antibodies yield therapeutic benefits.
• Investigational drugs (elumetinib, carbozantinib, refametinib) may enhance sorafenib efficacy.

Conclusions:

• Targeting multiple signaling pathways with combination regimens represents a promising approach for HCC.
• Clinical studies with novel agents are reshaping HCC management strategies.
• Advancements in combination therapy are improving standards of care and influencing clinical decisions for HCC patients.